GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Brooks Laboratories Ltd

Brooks Labs Q2 FY27 Standalone Net Profit Rs. 6,998.82 Lakhs, includes exceptional gain

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 07 Nov 2026, 05:54 PM IST  ·  BSE ID: 1ea50c53-65a0-4e07-a42b-105b6f29c12e
View Original BSE Filing (PDF)
💡
In Simple Terms
Brooks Laboratories reported a large profit increase, mainly from selling a part of its investment in another company.
🤖 AI Summary
  • Standalone Net Profit for Q2 FY27 was Rs. 6,998.82 Lakhs, significantly boosted by an exceptional gain.
  • Consolidated Net Profit for Q2 FY27 stood at Rs. 6,582.31 Lakhs.
  • Company recognized Rs. 7,470.00 Lakhs as exceptional income from partial divestment of Brooks Steriscience Limited stake.
  • Divestment involved selling 11.48% equity in Brooks Steriscience Limited for Rs. 7,473.60 Lakhs.
  • Standalone Revenue from operations for Q2 FY27 was Rs. 1,924.79 Lakhs.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Net Profit (Q2 FY27)
6,998.82 Lakhs
Not comparable — limited prior period data.
Consolidated Net Profit (Q2 FY27)
6,582.31 Lakhs
Not comparable — limited prior period data.
Exceptional Items Income (Q2 FY27)
7,470.00 Lakhs
Standalone Revenue from operations (Q2 FY27)
1,924.79 Lakhs
Not comparable — limited prior period data.
Share of loss from Brooks Steriscience Limited (Half Year Ended 30 Sep 2026)
558.37 Lakhs
🏢 How This Affects the Company
📈
Business Impact
The partial divestment of Brooks Steriscience Limited (BSL) reduces the company's direct shareholding in BSL from 49.00% to 37.52%. The company continues to retain significant influence over BSL's activities.
💰
Financial Impact
The exceptional gain of Rs. 7,470.00 Lakhs from the divestment significantly enhanced the net profit for Q2 FY27. This transaction also provided aggregate consideration of Rs. 7,473.60 Lakhs.
⚠️
Risk Impact
The company's share of loss from Brooks Steriscience Limited for the half year ended 30 September 2026 was Rs. 558.37 Lakhs. The partial divestment potentially reduces exposure to BSL's losses proportionate to the reduced shareholding.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, particularly the significant exceptional gain which increased net profit for Q2 FY27. The partial divestment alters the company's proportional ownership in Brooks Steriscience Limited.
🔍
Management Signal
Management completed a strategic partial divestment of an equity stake in an associate company, indicating a move to realize value or adjust portfolio exposure. The continued retention of significant influence in BSL highlights a long-term interest.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — assess revenue from operations trends post divestment.
Updates on Brooks Steriscience Limited's performance and impact on consolidated results.
Further details on utilization of the Rs. 7,473.60 Lakhs proceeds from the divestment.
MEDIUM RISK Heavy reliance on exceptional gain for profitability; underlying operational revenue declined year-over-year.
💡 Investor Takeaway
Brooks Laboratories reported standalone net profit of Rs. 6,998.82 Lakhs for Q2 FY27. This includes an exceptional gain of Rs. 7,470.00 Lakhs from the partial divestment of 11.48% equity stake in Brooks Steriscience Limited for Rs. 7,473.60 Lakhs. Standalone revenue from operations for Q2 FY27 was Rs. 1,924.79 Lakhs.
⚖️ Strengths & Concerns

✅ Positives

  • Exceptional gain of Rs. 7,470.00 Lakhs from divestment bolstered standalone net profit to Rs. 6,998.82 Lakhs in Q2 FY27.
  • Consolidated Net Profit for Q2 FY27 recorded Rs. 6,582.31 Lakhs.

⚠️ Concerns

  • Standalone revenue from operations decreased to Rs. 1,924.79 Lakhs in Q2 FY27 from Rs. 2,345.07 Lakhs in Q2 FY26.
  • Standalone profit before exceptional items and tax declined to Rs. 60.50 Lakhs in Q2 FY27 from Rs. 223.73 Lakhs in Q2 FY26.
📅 Company Track Record
A past filing dated 2026-11-07 for the same period highlighted the Q2 FY27 Standalone Net Profit of Rs. 6,998.82 Lakhs and specified the Rs. 7,470.00 Lakhs exceptional gain that boosted it.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Brooks Laboratories' standalone net profit for Q2 FY27?
Brooks Laboratories reported a standalone net profit of Rs. 6,998.82 Lakhs for the quarter ended 30 September 2026 (Q2 FY27).
What was the exceptional item reported in Q2 FY27 financial results?
The company reported an exceptional income of Rs. 7,470.00 Lakhs during Q2 FY27, recognized from the partial divestment of its equity stake in Brooks Steriscience Limited.
How much revenue from operations did Brooks Laboratories record in Q2 FY27?
Brooks Laboratories recorded standalone revenue from operations of Rs. 1,924.79 Lakhs for the quarter ended 30 September 2026 (Q2 FY27).
What was Brooks Laboratories' share of loss from Brooks Steriscience Limited for the half year ended September 30, 2026?
The company's share of loss after tax from Brooks Steriscience Limited for the half year ended 30 September 2026 amounted to Rs. 558.37 Lakhs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.